Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 13, 2017 in Melanoma | 0 comments

In a nutshell

This study compared survival rates in advanced melanoma patients treated with either pembrolizumab (Keytruda) or ipilimumab (Yervoy). The study found that patients treated with pembrolizumab had a higher survival rate and fewer overall side effects.

Some background

Both pembrolizumab and ipilimumab are treatments that affect the body’s immune system. Each therapy attaches to a different protein on the cancer cells. This allows the immune system to detect cancer cells in the body and destroy them. Pembrolizumab has been shown to increase the time to disease progression compared to ipilimumab, with fewer side effects. However, the long-term outcomes of these patients must be compared.

Methods & findings

This study compared the long-term survival in patients treated with pembrolizumab or ipilimumab.

834 patients with advanced melanoma took part in the trial. 279 (34.4%) received pembrolizumab every 2 weeks, 277 (34%) received pembrolizumab every 3 weeks and 278 (34.8%) patients received ipilimumab every 3 weeks. These treatments were randomly assigned to patients. Patients were followed for an average of 22.9 months.

After 24 months, 31% of patients on pembrolizumab every two weeks had not progressed. This was 28% in the 3-week group, and 14% in the ipilimumab group.

Average 2-year overall survival (time from treatment until death from any cause) was 55% in the pembrolizumab 2-week group55% in the 3-week group, and 43% in the ipilimumab group.

Common side effects reported from treatment were tiredness, itchy skin, rash and diarrhea. More serious treatment-related side effects were found in the ipilimumab group.

The bottom line

This study concluded that pembrolizumab was associated with improved survival rates compared to ipilimumab

Published By :

Lancet (London, England)

Date :

Aug 16, 2017

Original Title :

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

click here to get personalized updates